Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted fluorescence endoscopy with cetuximab-800CW for unknown primary head and neck cancer
NL-OMON59499Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab-IRDye 800CW in head and neck cancer (HNC), sponsored by University Medical Center Groningen. Primary endpoints: Macroscopic fluorescent signal levels and tracer distribution observed with targeted fluorescence endoscopy and Detection rates of targeted fluorescence endoscopy and white light endoscopy. Started Nov 2024; status: active, not recruiting.
02
Drugs
cetuximab-IRDye 800CW
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NL-OMON59499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59499.